{"id":4259,"date":"2024-03-07T09:49:08","date_gmt":"2024-03-07T09:49:08","guid":{"rendered":"https:\/\/zobio.com\/?p=4259"},"modified":"2026-04-02T09:51:57","modified_gmt":"2026-04-02T09:51:57","slug":"fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors","status":"publish","type":"post","link":"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/","title":{"rendered":"Fragment-Based Lead Discovery as a Powerful Approach for Identifying Novel SOS2: KRAS PPI Inhibitors"},"content":{"rendered":"

Fragment-Based Lead Discovery as a Powerful Approach for Identifying Novel SOS2: KRAS PPI Inhibitors <\/h2>\n
\n\t

The recent publication<\/a> in the Journal of Medicinal Chemistry by Mirati Therapeutics, ZoBio and Inixium nicely demonstrates the power of biophysics, structural biology and fragments to address an important target in cancers originating from KRAS mutant cells. This research introduces the idea of SOS2:KRAS p<\/strong>rotein-p<\/strong>rotein i<\/strong>nteraction (PPI) inhibitors, which complement existing SOS1:KRAS inhibitors, offering a promising avenue for the inhibition of KRAS signaling in cancer therapy.<\/p>\n

SOS1 is considered the primary g<\/strong>uanine e<\/strong>xchange f<\/strong>actor (GEF) for KRAS, which results in the conversion of KRAS from the inactive, GDP-bound state, to the active GTP-bound state. Gain of function mutation in SOS1 have been found in different types of tumours (c.f. here<\/a>) and multiple inhibitors of its interaction with KRAS have been presented (c.f. here<\/a>, here <\/a>or here<\/a>). However, there is evidence that SOS2 plays an important role in mediating PI3K signalling (c.f. here <\/a>and here<\/a>) and in resistance to SOS1 inhibitors (here<\/a>). Therefore, inhibition of SOS2-KRAS interaction could also be of therapeutic benefit.<\/p>\n

The strategy outlined in the paper involves F<\/strong>ragment-B<\/strong>ased L<\/strong>ead D<\/strong>iscovery (FBLD).\u00a0Through a combination of S<\/strong>urface P<\/strong>lasmon R<\/strong>esonance (SPR), T<\/strong>arget I<\/strong>mmobilized N<\/strong>MR S<\/strong>creen (TINS) \u00a0and X-ray crystallographic fragment-based screens, the researchers identified five fragment hits. Four of the hits displayed SOS2 binding KDs in the range 0.3\u22122mM, while SOS2 binding affinity could not be determined for the fifth compound. Further optimization of these hits, guided by X-ray cocrystal structures, will pave the way for the development of potent SOS2:KRAS PPI inhibitors, potentially offering new therapeutic options for KRAS-driven cancers and related disorders.<\/p>\n

This study once more highlights the potential of FBLD as a powerful approach for drug discovery and exemplifies the type of expertise-based interactions the ZoBio team has with its clients.<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

The recent publication in the Journal of Medicinal Chemistry by Mirati Therapeutics, ZoBio and Inixium nicely demonstrates the power of biophysics, structural biology and fragments to address an important…<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"gpsa_enabled":false,"gpsa_required_form_ids":[],"gpsa_require_unique_form_submission":false,"gpsa_access_behavior":"show_message","gpsa_form_redirect_path":"","gpsa_requires_access_message":"Access to this content requires submission of a form.","gpsa_access":{"type":"session","duration":{"value":30,"unit":"days"}},"gpsa_content_loading_message":"Please wait while we process your submission.","footnotes":""},"categories":[3],"tags":[],"class_list":["post-4259","post","type-post","status-publish","format-standard","hentry","category-news"],"yoast_head":"\nFragment-Based Lead Discovery as a Powerful Approach for Identifying Novel SOS2: KRAS PPI Inhibitors - ZoBio - Drug Discovery Technology<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fragment-Based Lead Discovery as a Powerful Approach for Identifying Novel SOS2: KRAS PPI Inhibitors - ZoBio - Drug Discovery Technology\" \/>\n<meta property=\"og:description\" content=\"The recent publication in the Journal of Medicinal Chemistry by Mirati Therapeutics, ZoBio and Inixium nicely demonstrates the power of biophysics, structural biology and fragments to address an important...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/\" \/>\n<meta property=\"og:site_name\" content=\"ZoBio - Drug Discovery Technology\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-07T09:49:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-02T09:51:57+00:00\" \/>\n<meta name=\"author\" content=\"Content manager ~KB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Content manager ~KB\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/\"},\"author\":{\"name\":\"Content manager ~KB\",\"@id\":\"https:\/\/zobio.com\/online\/#\/schema\/person\/fcdd542fb16960e243f01d731e59d707\"},\"headline\":\"Fragment-Based Lead Discovery as a Powerful Approach for Identifying Novel SOS2: KRAS PPI Inhibitors\",\"datePublished\":\"2024-03-07T09:49:08+00:00\",\"dateModified\":\"2026-04-02T09:51:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/\"},\"wordCount\":320,\"publisher\":{\"@id\":\"https:\/\/zobio.com\/online\/#organization\"},\"articleSection\":[\"News\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/\",\"url\":\"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/\",\"name\":\"Fragment-Based Lead Discovery as a Powerful Approach for Identifying Novel SOS2: KRAS PPI Inhibitors - ZoBio - Drug Discovery Technology\",\"isPartOf\":{\"@id\":\"https:\/\/zobio.com\/online\/#website\"},\"datePublished\":\"2024-03-07T09:49:08+00:00\",\"dateModified\":\"2026-04-02T09:51:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/zobio.com\/online\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fragment-Based Lead Discovery as a Powerful Approach for Identifying Novel SOS2: KRAS PPI Inhibitors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/zobio.com\/online\/#website\",\"url\":\"https:\/\/zobio.com\/online\/\",\"name\":\"ZoBio - Drug Discovery Technology\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/zobio.com\/online\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/zobio.com\/online\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/zobio.com\/online\/#organization\",\"name\":\"ZoBio - Drug Discovery Technology\",\"url\":\"https:\/\/zobio.com\/online\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/zobio.com\/online\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/zobio.com\/online\/wp-content\/uploads\/2020\/01\/primary_logo_diap-ZoBio-RGBS.png\",\"contentUrl\":\"https:\/\/zobio.com\/online\/wp-content\/uploads\/2020\/01\/primary_logo_diap-ZoBio-RGBS.png\",\"width\":300,\"height\":371,\"caption\":\"ZoBio - Drug Discovery Technology\"},\"image\":{\"@id\":\"https:\/\/zobio.com\/online\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/zobio.com\/online\/#\/schema\/person\/fcdd542fb16960e243f01d731e59d707\",\"name\":\"Content manager ~KB\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/zobio.com\/online\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1e15929286368ee5275559d8b4bedc4a09a64b8968513d7c2286c3fd17fe93ee?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1e15929286368ee5275559d8b4bedc4a09a64b8968513d7c2286c3fd17fe93ee?s=96&d=mm&r=g\",\"caption\":\"Content manager ~KB\"},\"url\":\"https:\/\/zobio.com\/online\/author\/kasia\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fragment-Based Lead Discovery as a Powerful Approach for Identifying Novel SOS2: KRAS PPI Inhibitors - ZoBio - Drug Discovery Technology","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/","og_locale":"en_GB","og_type":"article","og_title":"Fragment-Based Lead Discovery as a Powerful Approach for Identifying Novel SOS2: KRAS PPI Inhibitors - ZoBio - Drug Discovery Technology","og_description":"The recent publication in the Journal of Medicinal Chemistry by Mirati Therapeutics, ZoBio and Inixium nicely demonstrates the power of biophysics, structural biology and fragments to address an important...","og_url":"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/","og_site_name":"ZoBio - Drug Discovery Technology","article_published_time":"2024-03-07T09:49:08+00:00","article_modified_time":"2026-04-02T09:51:57+00:00","author":"Content manager ~KB","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Content manager ~KB","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/#article","isPartOf":{"@id":"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/"},"author":{"name":"Content manager ~KB","@id":"https:\/\/zobio.com\/online\/#\/schema\/person\/fcdd542fb16960e243f01d731e59d707"},"headline":"Fragment-Based Lead Discovery as a Powerful Approach for Identifying Novel SOS2: KRAS PPI Inhibitors","datePublished":"2024-03-07T09:49:08+00:00","dateModified":"2026-04-02T09:51:57+00:00","mainEntityOfPage":{"@id":"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/"},"wordCount":320,"publisher":{"@id":"https:\/\/zobio.com\/online\/#organization"},"articleSection":["News"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/","url":"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/","name":"Fragment-Based Lead Discovery as a Powerful Approach for Identifying Novel SOS2: KRAS PPI Inhibitors - ZoBio - Drug Discovery Technology","isPartOf":{"@id":"https:\/\/zobio.com\/online\/#website"},"datePublished":"2024-03-07T09:49:08+00:00","dateModified":"2026-04-02T09:51:57+00:00","breadcrumb":{"@id":"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/zobio.com\/online\/news\/fragment-based-lead-discovery-as-a-powerful-approach-for-identifying-novel-sos2kras-ppi-inhibitors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/zobio.com\/online\/"},{"@type":"ListItem","position":2,"name":"Fragment-Based Lead Discovery as a Powerful Approach for Identifying Novel SOS2: KRAS PPI Inhibitors"}]},{"@type":"WebSite","@id":"https:\/\/zobio.com\/online\/#website","url":"https:\/\/zobio.com\/online\/","name":"ZoBio - Drug Discovery Technology","description":"","publisher":{"@id":"https:\/\/zobio.com\/online\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/zobio.com\/online\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/zobio.com\/online\/#organization","name":"ZoBio - Drug Discovery Technology","url":"https:\/\/zobio.com\/online\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/zobio.com\/online\/#\/schema\/logo\/image\/","url":"https:\/\/zobio.com\/online\/wp-content\/uploads\/2020\/01\/primary_logo_diap-ZoBio-RGBS.png","contentUrl":"https:\/\/zobio.com\/online\/wp-content\/uploads\/2020\/01\/primary_logo_diap-ZoBio-RGBS.png","width":300,"height":371,"caption":"ZoBio - Drug Discovery Technology"},"image":{"@id":"https:\/\/zobio.com\/online\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/zobio.com\/online\/#\/schema\/person\/fcdd542fb16960e243f01d731e59d707","name":"Content manager ~KB","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/zobio.com\/online\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1e15929286368ee5275559d8b4bedc4a09a64b8968513d7c2286c3fd17fe93ee?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1e15929286368ee5275559d8b4bedc4a09a64b8968513d7c2286c3fd17fe93ee?s=96&d=mm&r=g","caption":"Content manager ~KB"},"url":"https:\/\/zobio.com\/online\/author\/kasia\/"}]}},"_links":{"self":[{"href":"https:\/\/zobio.com\/online\/wp-json\/wp\/v2\/posts\/4259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zobio.com\/online\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zobio.com\/online\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zobio.com\/online\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/zobio.com\/online\/wp-json\/wp\/v2\/comments?post=4259"}],"version-history":[{"count":5,"href":"https:\/\/zobio.com\/online\/wp-json\/wp\/v2\/posts\/4259\/revisions"}],"predecessor-version":[{"id":4764,"href":"https:\/\/zobio.com\/online\/wp-json\/wp\/v2\/posts\/4259\/revisions\/4764"}],"wp:attachment":[{"href":"https:\/\/zobio.com\/online\/wp-json\/wp\/v2\/media?parent=4259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zobio.com\/online\/wp-json\/wp\/v2\/categories?post=4259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zobio.com\/online\/wp-json\/wp\/v2\/tags?post=4259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}